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Objective: We sought to determine whether the Cox maze procedure provides
additional benefit to patients with atrial fibrillation undergoing mitral valve opera-
tions.
Methods: Between May 1992 and August 2000, we performed 258 Cox maze
procedures with mitral valve replacement (n  147) or mitral valve repair (n 
111). We compared the outcomes of these patients with those of 61 control patients
with preoperative atrial fibrillation who underwent mitral valve replacement alone
during the same interval. The three cohorts were similar in age, sex, and proportion
of patients in preoperative New York Heart Association functional class 3 or 4.
Results: Although 5-year survivals were similar among the groups (94% for mitral
valve replacement alone, 95% for mitral valve replacement plus maze, and 97% for
mitral valve repair plus maze), freedoms from atrial fibrillation at 5 years were
significantly higher in the mitral valve replacement plus maze group (78%) and the
mitral valve repair plus maze group (81%) than in the mitral valve replacement
group (6%, P  .0001). Freedoms from stroke at 5 years were 97% for the mitral
valve replacement plus maze group, 97% for the mitral valve repair plus maze
group, and only 79% for mitral valve replacement group (P .0001). Multivariable
analysis with Cox hazard model revealed that the most significant risk factor for late
stroke was the omission of the Cox maze procedure (P  .003).
Conclusions: The addition of the Cox maze procedure to mitral valve repair and
replacement was safe and effective for selected patients. Elimination of atrial
fibrillation significantly decreased the incidence of late stroke.
Approximately 40% to 60% of patients who undergo mitral valvesurgery have chronic atrial fibrillation before the operation,1-3 andmost remain in atrial fibrillation after the operation.4 Althoughseveral authors have reported that atrial fibrillation can be suc-cessfully ablated with the Cox maze procedure in patients under-going mitral valve procedures,5,6 few studies have demonstrated a
long-term benefit in terms of reduced late morbidity and mortality associated with
the elimination of atrial fibrillation.7 Several studies have reported the benefit of a
Cox maze procedure combined with mitral valve repair. However, most surgeons do
not perform a maze procedure in patients who require mitral valve replacement,
especially with mechanical valves, because most of these patients will be maintained
on systemic anticoagulation, which is presumed to result in a low risk of postop-
erative thromboembolism. Although anticoagulation is beneficial, however, it does
From the Departments of Cardiovascular
Surgerya and Cardiology,c National Cardio-
vascular Center, Osaka, and Takarazuka
Municipal Hospital,b Takarazuka, Japan.
Read at the Eighty-first Annual Meeting of
The American Association for Thoracic
Surgery, San Diego, Calif, May 6-9, 2001.
Received for publication May 15, 2001;
revisions requested July 27, 2001; revisions
received Dec 20, 2001; accepted for publi-
cation Dec 27, 2001.
Address for reprints: Ko Bando, MD, De-
partment of Cardiovascular Surgery, Na-
tional Cardiovascular Center, 5-7-1, Fu-
jishirodai, Suita, Osaka, 565-8565, Japan
(E-mail: kobando@hosp.ncvc.go.jp).
J Thorac Cardiovasc Surg 2002;124:575-83
Copyright © 2002 by The American Asso-
ciation for Thoracic Surgery
0022-5223/2002 $35.000 12/6/124392
doi:10.1067/mtc.2002.124392
Bando et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 124, Number 3 575
A
CD
not abolish the risk of stroke associated with atrial fibrilla-
tion.7 We have used the Cox maze procedure in conjunction
with both mitral valve repair and replacement (even with
mechanical valves) in patients with significant mitral dis-
ease and atrial fibrillation in the expectation of a lower risk
of thromboembolism and improved cardiac function when
sinus rhythm is maintained. The purpose of this study was
to assess the early- and late-term results of a Cox maze
procedure combined with mitral valve repair or replace-
ment.
Patients and Methods
Between May 1992 and September 2000, we performed 258 Cox
maze procedures combined with mitral valve replacement (MVR/
maze, n  147) or repair (MVP/maze, n  111) at the National
Cardiovascular Center, Osaka, Japan. We compared the outcomes
of these patients with those of 61 patients with preoperative atrial
fibrillation who underwent MVR alone during the same interval.
We retrospectively reviewed the data from operative notes,
anesthesia records, clinical case histories, and laboratory investi-
gations, including electrocardiograms, echocardiograms, and car-
diac catheterization reports. Follow-up data were collected from
National Cardiovascular Center records of outpatient visits and
correspondence with referring physicians. A total of 319 clinical
hemodynamic, electrocardiographic, and echocardiographic vari-
ables were entered into a computerized database and analyzed.
Follow-up data for more than 6 months after the operations were
available for all patients. Morbid events were analyzed for both the
early (in hospital) and late (after discharge) periods. Stroke was
defined as cerebral thromboembolism and was clearly differenti-
ated from transient ischemic attack.
Patients
Demographic data and preoperative cardiac information are given
in Table 1. Although the proportions of patients with left atrial
thrombus were similar in all groups, the MVR/maze group had a
higher incidence of previous stroke. Patients who underwent MVR
alone had a higher incidence of previous heart surgery (Table 1).
With respect to preoperative heart rhythm, most patients in each
group had chronic atrial fibrillation. A maze procedure combined
with mitral valve repair (MVP/maze; n  4) or replacement
(MVR/maze; n  3) was performed for 7 patients who had
multiple episodes of paroxysmal atrial fibrillation necessitating
long-term anticoagulation. The duration of preoperative atrial fi-
brillation was significantly longer among patients with MVR alone
than among patients who underwent MVP/maze or MVR/maze
(Table 1). Patients undergoing MVR without a maze procedure
had the maze procedure omitted primarily because of multiple
previous heart operations, duration of preoperative atrial fibrilla-
tion longer than 20 years, f-wave in V1 leads less than 0.1 mV, left
atrial dimension larger than 70 mm, and emergency surgery.
Surgical Procedure
Most patients in the MVR group (n  57/61) and the MVR/maze
group (n  143/147) received mechanical valves. Methods of
mitral valve repair in the MVP/plus maze group varied according
to the pathologic findings. The Cox maze II/III, Kosakai maze, and
further modification of Kosakai maze (cryomaze) procedures were
used (Figure 1).7-9 In the Kosakai maze procedure, cryoablation
was used to avoid cutting the sinus node artery, which may result
in sick sinus syndrome. A modification of the Kosakai maze
procedure included use of cryoablation around the edge of the left
pulmonary veins, avoiding the incision encircling all four orifices
of the pulmonary veins.
Statistical Methods
Comparisons of the characteristics in the three groups were per-
formed with a 2 test for nominal variables and a nonparametric
analysis of variance followed by a post hoc Bonferroni test for
continuous and ordinal variables. Survivals and freedoms from
atrial fibrillation and stroke were estimated by the Kaplan-Meier
method. Survival curves were compared with a log-rank test. The
risks for recurrence of atrial fibrillation and stroke were analyzed
by both univariate analysis and multivariate analysis with the Cox
proportional hazards model.
Results
Pathophysiologic Characteristics of Mitral Valve
Disease and Operative Findings
The pathophysiologic characteristics of the mitral valve
disease and the concomitant procedures are depicted in
Table 2. There were no significant differences between the
groups in terms of the incidence of associated procedures.
All patients underwent surgery with mild hypothermia and
TABLE 1. Preoperative clinical characteristics
Variable MVR MVR/maze MVP/maze P value
Sex (male/female ratio) 28:33 55:92 70:41 —
Age (y, mean  SD) 62.9 8.6 58.8 8.3 59.4 11.0 —
New York Heart Association class III or
IV (No.)
33 (54.1%) 69 (46.9%) 41 (36.9%) .051
History of stroke (No.) 11 (19.6%) 36 (24.5%) 7 (6.3%) .001
Left atrial thrombus (No.) 2 (3.6%) 11 (7.5%) 6 (5.4%) .56
Previous heart surgery (No.) 28 (45.9%) 24 (16.3%) 6 (5.4%) .0001
Chronic atrial fibrillation (No.) 61 (100%) 143 (97.3%) 105 (94.6%) .16
Preoperative f wave 0.1 mV (No.) 49 (80.3%) 14 (9.5%) 5 (4.5%) .0001
Duration of atrial fibrillation 20 y (No.) 28 (45.9%) 23 (15.6%) 11 (9.9%) .0001
Surgery for Acquired Cardiovascular Disease Bando et al
576 The Journal of Thoracic and Cardiovascular Surgery ● September 2002
A
CD
Figure 1. Techniques of maze procedure performed in this study. A, Cox maze III procedure; B, Kosakai maze
procedure; C, Cryomaze procedure. SVC, Superior vena cava; RAA, right atrial appendage; LAA, left atrial
appendage; LSA, left sinus node artery; RSA, right sinus node artery; SN, sinus node, PSA, posterior sinus node
artery; IVC, inferior vena cava; MV, mitral valve; TV, tricuspid valve; FO, foramen ovale.
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combined antegrade and retrograde blood cardioplegia. The
aortic crossclamp times and cardiopulmonary bypass times
were not significantly different among the groups. The
proportions of patients who underwent concomitant ligation
of the left atrial appendage were similar among the groups
(MVR, n  45/61, 74%, MVR/maze, n  102/147, 69%,
and MVP/maze, n  77/111, 70%, P  .79).
Postoperative Morbidity and Mortality
In-hospital deaths included 1 patient who underwent MVR
(low output syndrome), 2 patients in the MVR/maze group
(multiple organ failure), and 2 patients in the MVP/maze
group (mediastinitis in 1 case and multiple organ failure in
1 case). Postoperative complications included bleeding (n
7), intraoperative balloon pump insertion (n  2), medias-
tinitis (n  2), left ventricular assist device insertion (n 
1), pneumothorax (n  1), and renal failure (n  1). There
were no differences among the three cohorts in the inci-
dence of complications.
Survival and Late Outcomes
All patients were observed for at least 6 months after the
operation. Although the actuarial 5-year survival of the
patients with MVR alone (94%) was lower than those of the
MVR/maze (95%) and MVP/maze (97%) groups, this dif-
ference did not reach statistical significance (P  .18;
Figure 2). There were 10 late deaths. In the MVR alone
group, 2 patients died of unknown causes, 1 had intracere-
bral bleeding, 1 had cerebral infarction, and 1 died of an
arrhythmia. In the MVR/maze group, 4 late deaths were due
to intracerebral bleeding (n  1), arrhythmia (n  1), left
ventricular rupture (n  1), and pneumonia (n  1). In the
MVP/maze group, 1 late death was caused by liver cancer.
We chose to analyze the recurrence of arrhythmia after
the first 30 days because early postoperative atrial fibrilla-
tion may be caused by a mechanism that differs from that of
chronic atrial fibrillation. Freedom from atrial fibrillation
after 3 years was 6% in the MVR group, compared with
84% and 85% in the MVR/maze and MVP/maze groups
(P  .001; Figure 3).
Freedom from stroke after 5 years was 79% in the MVR
group, compared with 97% in the MVR/maze and MVP/
maze groups (P  .0001; Figure 4).
Electrocardiography
At the time of their discharge from the hospital, 81% to 83%
of patients in the combined MVP/maze and MVR/maze
groups were free of atrial fibrillation, compared with 5% in
the MVR group (P  .001; Table 3). Seventeen patients
required pacemaker implantation after the operation: 8 in
the MVR/maze group, 8 in the MVP/maze group, and 1 in
the MVR group. At the most recent follow-up, 72% to 76%
of patients in the MVR/maze and MVP/maze groups still
remained free of atrial fibrillation, compared with only 7%
of those in the control group (Table 3). A total of 16 patients
required permanent pacemaker implantation for profound
bradycardia with underlying atrial fibrillation after a com-
bined maze procedure and MVP or MVR (Table 3).
Late Functional Outcome
Preoperative New York Heart Association functional class
breakdowns were similar among the groups, whereas the
proportion of the patients in postoperative New York Heart
Association functional class II or higher was significantly
greater among the patients with MVR alone (n  20/56,
35.8%) than in the other two groups (MVR/maze, n 
14/145, 9.7%, MVP/maze, n  9/109, 8.3%, P  .001).
Preoperative and Postoperative Medications
The spectra and intensities of preoperative antiarrhythmic
drugs were comparable among the three cohorts, but after
the operation the number of antiarrhythmic agents de-
creased with time in the combined MVR/maze and MVP/
maze groups. At most recent follow-up, 35% of the patients
in the MVR/maze group and 48% of the patients in the
MVP/maze group needed no antiarrhythmic agents,
whereas only 13% of those in the MVR group did not need
these medications (P .0001). The vast majority of patients
in the MVR group continued to receive -blockers and
digoxin for heart rate control.
TABLE 2. Pathophysiologic characteristics of mitral disease and concomitant procedures
MVR
(n  61)
MVR/maze
(n  147)
MVP/maze
(n  111)
Pathophysiologic characteristics (No.)
Mitral stenosis 22 69
Mitral regurgitation 15 33 93
Mitral stenosis and regurgitation 5 31 5
Prosthetic valve failure 19 14 0
Concomitant procedures (No.)
Tricuspid annuloplasty 37 (60.7%) 59 (40.5%) 45 (40.5%)
Coronary artery bypass grafting 1 (1.6%) 5 (3.4%) 3 (2.7%)
Atrial septal defect closure 0 2 (1.4%) 7 (6.3%)
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With respect to warfarin, 100% of the patients in the
MVR group and 97% of the patients in the MVR/maze
group were receiving warfarin at most recent follow-up,
whereas only 35% of the patients in the MVP/maze group
required warfarin (P  .0001). In the MVP/maze group,
warfarin administration was continued for patients who
had at least one episode of postoperative atrial fibrilla-
tion.
Risk Factors for Recurrence of Atrial Fibrillation
Risk factors for recurrence of atrial fibrillation were ana-
lyzed by univariate and multivariable analyses. According
to univariate analysis, omission of the maze procedure and
duration of chronic atrial fibrillation for longer than 20 years
were significant risk factors for recurrence of atrial fibrilla-
tion. According to multivariable analysis, the omission of a
maze procedure and longer duration of chronic atrial fibril-
Figure 3. Freedom from recurrence of atrial fibrillation (AF) curves for MVP/maze (solid line, n  111), MVR/maze
(long and short dashed line, n  147), and MVR (dotted line, n  61) groups. Error bars indicate 95% confidence
interval. P < .0001 by log-rank test.
Figure 2. Actuarial survival curves for MVP/maze (solid line, n  111), MVR/maze (long and short dashed line, n 
147), and MVR (dotted line, n  61) groups. Error bars indicate 95% confidence interval. P  .1762 by log-rank test.
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lation were risk factors for recurrent atrial fibrillation (Table
4).
Incidence of Stroke After Surgery
During the hospital stay, 2 patients in the MVR group had
strokes (operation related in 1 case and inadequate antico-
agulation in 1 case) and 1 patient in the MVP/maze group
had a stroke (operation related). After discharge, 12 patients
had strokes related to recurrent atrial fibrillation. There were
10 strokes among patients who were receiving adequate
anticoagulation (6 in the MVR group, 2 in the MVR/maze
group, and 2 in the MVP/maze group). Another 2 patients
had strokes during periods of inadequate anticoagulation.
Risk Factors for Late Stroke
According to univariate analysis, the omission of a maze
procedure and recurrence of atrial fibrillation 1 month after
surgery or at the time of discharge were risk factors for late
stroke (Table 5). According to multivariate analysis, the
omission of a maze procedure was the most significant risk
factor for late stroke (Table 5). Except for 2 of the patients
in the MVR group, all patients had adequate anticoagulation
with warfarin at the time of any strokes.
Discussion
Atrial fibrillation, one of the most common forms of cardiac
arrhythmia, may cause significant morbid events, including
systemic embolism, hemodynamic compromise, palpita-
TABLE 3. Comparison of heart rhythms in each group
MVR MVR/maze MVP/maze
No. % No. % No. %
Rhythm at discharge
Normal sinus rhythm 3 5.0 118 81.4 90 82.6
Atrial fibrillation 57 95.0 22 15.2 10 9.2
Atrial flutter 0 0 2 1.4 4 3.7
Junctional 0 0 2 1.4 4 3.7
Pacing 0 0 0 1 0.9
Most recent follow-up rhythm
Normal sinus rhythm 3 5.0 105 72.4 83 76.1
Atrial fibrillation 56 93.3 30 20.7 16 14.7
Atrial flutter 0 0 0 0 0 0
Junctional 0 0 2 1.4 2 1.8
Pacing 1 1.7 8 5.5 8 7.3
Figure 4. Freedom from late stroke curves for MVP/maze (solid line, n  111), MVR/maze (long and short dashed
line, n  147), and MVR (dotted line, n  61) groups. Error bars indicate 95% confidence interval. P < .0001 by
log-rank test.
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tions, and adverse reactions to antiarrhythmic agents and
anticoagulants. The Cox maze procedure was designed to
prevent chronic and paroxysmal atrial fibrillation and flut-
ter, and several studies have confirmed the effectiveness of
this procedure. Encouraged by this early success, the indi-
cations have been extended from isolated atrial fibrillation
to the treatment of chronic atrial fibrillation in patients
undergoing other cardiac operations, including those for
mitral valve disease, atrial septal defects, coronary artery
disease, and Fontan circulation.10,11 However, few studies
have demonstrated a long-term benefit of this procedure in
reducing late morbidity and improving functional outcomes.
In our study more than 97% of patients who underwent
a combined maze procedure and mitral valve operation
survived the operations, and 95% to 97% of those patients
are still alive 5 years later (Figure 2). Furthermore, the
addition of maze procedures to the mitral valve operations
did not increase the number of morbid events in the imme-
diate postoperative period. These results confirm the safety
of a maze procedure as an adjunct to MVP or MVR.
Maintenance of normal sinus rhythm after a maze pro-
cedure improves atrial function.12 However, the most im-
portant potential benefit of the maze procedure is prevention
of late stroke.7 Our results indicated that a maze procedure
combined with a mitral valve operation restored regular
rhythm in 84% to 85% of patients at 3 years after surgery
(Figure 3), whereas only 6% of patients with MVR alone
avoided recurrent atrial fibrillation at 3 years after surgery.
Accordingly, 97% of these patients were free from late
stroke at 5 years after surgery, compared with only 79% of
patients who underwent MVR alone.
Some surgeons do not perform maze procedure in addi-
tion to MVR with mechanical valves because these patients
receive systemic anticoagulation after surgery. In our study,
however, 8 of the 10 late strokes among patients receiving
optimal anticoagulation with warfarin occurred after MVR
with mechanical valves. These results indicate that although
anticoagulation is beneficial, it does not abolish the risk of
stroke associated with atrial fibrillation.13-15 Furthermore,
these results indicate that the current anticoagulant strategy
of warfarin alone may not be adequate to prevent late
strokes among these patients.16
Risk factor analysis for late stroke revealed that the
omission of a maze procedure and recurrent atrial fibrilla-
tion at discharge were significant risks according to univar-
iate analysis (Table 5). According to multivariate analysis,
the omission of a maze procedure was the most significant
risk for the development of late stroke (Table 5). Moreover,
in the MVR/maze and MVP/maze groups, late strokes oc-
curred in 4 patients in whom atrial fibrillation recurred after
an unsuccessful maze procedure. These findings confirm
that the restoration of sinus rhythm after mitral valve sur-
gery by a maze procedure is the most effective means of
preventing late strokes.
The major limitation of our study is that it was not
randomized, and there were significant differences between
the baseline characteristics of patients in the MVR group
and the combined maze procedure groups. The decision for
or against an adjunct maze procedure reflected the surgeon’s
experience. As previously mentioned, however, we omitted
the maze procedure for most patients who had multiple
previous heart operations, preoperative atrial fibrillation for
longer than 20 years, f-wave in V1 leads less than 0.1 mV,
severely enlarged left atrial dimension greater than 70 mm,
or emergency surgery. Thus, the patients who underwent
MVR alone may have been at higher risk than those who
TABLE 4. Results of univariate and multivariate analyses of risk factors for recurrence of atrial fibrillation
Variable
Univariate analysis
P value
Multivariate analysis
P
value Hazard ratio
95% Confidence
interval
No Cox maze procedure .0001 .028 2.26 1.09-4.67
Preoperative left atrial dimension 70 mm .0029 .39 1.46 0.62-3.16
Duration of chronic atrial fibrillation 20 y .001 .0001 3.67 1.89-7.11
TABLE 5. Results of univariate and multivariate analyses of risk factors for late stroke
Variable
Univariate analysis
P value
Multivariate analysis
P
value Hazard ratio
95% Confidence
interval
No Cox maze procedure .0001 .0038 9.9 2.10-46.8
Preoperative left atrial dimension 70 mm .059 — — —
Duration of chronic atrial fibrillation 20 y .13 .73 1.24 0.38-4.02
Recurrent atrial fibrillation at discharge .0013 .39 2.16 0.38-12.45
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underwent combined procedures. This may be the primary
reason for a somewhat lower late survival among the pa-
tients with MVR alone than among the patients in the other
two groups. Another limitation of this study is that only
some of the patients in each group underwent preoperative
and postoperative cardiopulmonary exercise tests. Although
most patients in each group were in New York Heart As-
sociation functional class I or II after the operation, further
study to assess the late functional outcomes should be
conducted. Although this study confirms the importance of
maintaining sinus rhythm in the prevention of late strokes,
the precise mechanism behind this process remains unclear.
A prospective study would be needed to differentiate the
roles of arrhythmia, cardiac function, microbubbles, and
other factors in the occurrence of stroke and to determine
the most effective regimen of anticoagulation and antiplate-
let agents to minimize the risk of late bleeding and stroke.
We conclude that the addition of the Cox maze proce-
dure to MVP and MVR is safe and effective for selected
patients. The incidence of late stroke was significantly de-
creased in patients undergoing combined maze and mitral
valve procedures.
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Discussion
Dr Renee Hartz (New Orleans, La). Although Bando and
coworkers have clearly demonstrated a marked reduction in mor-
bidity after mitral valve surgery when a maze procedure or a
variant of the maze procedure was added to the operation, the
validity of referring to a “control” group in this series can be
questioned. Perhaps statistical comparisons have been meaningful
or more valid if the groups had been referred to as “treatment” and
“nontreatment” groups.
Specifically, Dr Bando, please address the following issues.
First, in the MVR/maze group, did you consider simply ligating
the atrial appendage, with or without adding a reduction in atrial
size? With closely monitored anticoagulation, might you not have
observed the same freedom from stroke at 5 years as you did with
the maze procedure itself?
Second, in the MVP/maze group, the incidence of chronic atrial
fibrillation was very high (95%), yet 85% of this cohort had pure
mitral regurgitation and therefore presumably degenerative patho-
physiology. Yesterday we learned from Carpentier and colleagues
that 60% of the patients in their group with degenerative disease
were in normal sinus rhythm after the operation. Can you reconcile
this difference? Are you seeing patients later in the course of the
disease than are surgeons in some our countries?
By extension, why was your freedom from stroke in this group,
the MVP/maze group, only 78% at 5 years? In your article, you
refer to “periods of inadequate anticoagulation.” Who monitors
your patients, and what is your chosen target international normal-
ized ratio?
Finally, did you consider routine appendage ligation in all
cases, even in your supposed control group? And did you consider
ablation only with mapping techniques in extremely high-risk
cases, ablating the site of origin, which we know can be deter-
mined before or during the operation?
It has been stated at this meeting and elsewhere that the maze
procedure is the criterion standard for the curative treatment of
atrial fibrillation. It has been a privilege to discuss this work,
especially at a meeting where several presentations have docu-
mented expanding indications for this important operation and at
which the presidential address was delivered by its inventor. You
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and your group should be commended for reducing the incidence
of stroke by any means available in a large group of patients with
valvular heart disease who are therefore at high risk for stroke.
Dr Bando. Regarding your first question, part of the answer is
that it may not be appropriate to call the MVR alone group a
“control” group. As you are aware, this was a nonrandomized
retrospective study, and the background characteristics of these
three cohorts were different. However, the key message in my
presentation is that if you do not do a maze procedure and chronic
atrial fibrillation continues, that is the most significant risk factor
for late stroke, and in that regard I believe that our observation is
valid.
Your second question is whether simple ligation of appendage
and the reduction of left atrial size may result in the same effect as
the maze operation of preventing late stroke. I think that the
answer is no. As indicated in my presentation, 2 patients in the
maze group had late strokes after unsuccessful maze procedures,
although these patients had left atrial appendage ligation and were
receiving adequate anticoagulation at the time of the stroke. Thus,
the maintenance of a regular rhythm and re-establishment of atrial
contraction is important in preventing stroke.
The third question relates to the MVP in the maze group. As
you mentioned, 85% of this group had mitral regurgitation, but this
included predominant mitral regurgitation, and some patients had
a component of mitral stenosis as well. Therefore, this does not
represent pure mitral regurgitation. In this group 45% of the
patients had rheumatic changes, and this probably resulted in the
difference between the Western population and the Japanese pop-
ulation. That may be the reason for the difference between our data
and those of Carpentier and colleagues.
Our target international normalized ratio, which is monitored
by our cardiologists at the National Cardiovascular Center and by
a local physician, is 2.0 to 3.0. This is somewhat lower than the
Western standard, but it is based on the preparing guidelines of the
Japanese Circulation Society and American College of Chest Phy-
sicians.
Finally, would I ligate all atrial appendages? As I mentioned
before, I preserve the appendage to maintain the production of
atrial natriuretic peptide, but I tie from the outside if I do not have
enough time or close from the inside while preserving the append-
age.
Dr Lawrence Cohn (Brookline, Mass). I assume these were
the classic surgical interruptions of the tracts in the atrium. Do you
have experience with the newer radiofrequency techniques? Do
you use these at all?
Dr Bando. Actually, we have just started and have done 1 case.
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